Gyre Therapeutics, Inc. (GYRE)

NASDAQ: GYRE · Real-Time Price · USD

7.98

+0.08 (1.01%)

Dec 5, 2025, 4:00 PM EST - Market closed

Gyre Therapeutics Employees

Gyre Therapeutics had 579 employees as of December 31, 2024. The number of employees decreased by 14 or -2.36% compared to the previous year.

Employees

579

Change (1Y)

-14

Growth (1Y)

-2.36%

Revenue / Employee

$185,259

Profits / Employee

$11,487

Market Cap

725.31M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	579	-14	-2.36%
Dec 31, 2023	593	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

GYRE News

4 weeks ago - Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update - GlobeNewsWire
7 weeks ago - Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis - GlobeNewsWire
7 weeks ago - Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025 - GlobeNewsWire
3 months ago - Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
3 months ago - Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker - Benzinga
3 months ago - Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors - GlobeNewsWire
4 months ago - Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update - GlobeNewsWire
6 months ago - Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China - GlobeNewsWire